Y.B Urban Renewal - Residential Development LTD
CSURE-M | TA
Overview
Corporate Details
- ISIN(s):
- IL0001110134
- LEI:
- Country:
- Israel
- Address:
- 2 Hahadarim Street, 7712102 Ashdod
- Website:
- https://www.yb-i.co.il/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cannassure-M focuses on the development and production of medical cannabis products in Israel.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-15 19:43 |
Regulatory Filings
Trading in the company's shares (ISIN IL0001110134) will be renewed on Monday, …
|
Hebrew (modern) | 113.5 KB | ||
| 2025-05-05 15:53 |
Regulatory Filings
The securities not included in the Illiquid list as of May 4th
2025 due to mar…
|
Hebrew (modern) | 217.1 KB | ||
| 2025-05-05 11:32 |
Regulatory Filings
Suspension of trading due to failure in publication of financial reports s for …
|
Hebrew (modern) | 79.7 KB | ||
| 2025-04-28 18:40 |
Regulatory Filings
Securities that have joined the program and the Market Makers that will operate…
|
Hebrew (modern) | 366.8 KB | ||
| 2025-04-20 18:21 |
Regulatory Filings
Failure in publishing financial reports-Notification
|
Hebrew (modern) | 128.0 KB | ||
| 2025-03-06 18:39 |
Regulatory Filings
Illiquid Candidates securities list as of May 4th 2025
|
Hebrew (modern) | 245.6 KB | ||
| 2024-07-28 18:05 |
Regulatory Filings
The company's securities will be transferred from the maintenance list to the m…
|
Hebrew (modern) | 106.5 KB | ||
| 2024-07-11 17:14 |
Regulatory Filings
Changes in the company's share symbol correction: YBRD-M
|
Hebrew (modern) | 104.0 KB | ||
| 2024-07-09 17:01 |
Regulatory Filings
Changes in the company's name and security, effective as of July 11, 2024
|
Hebrew (modern) | 105.9 KB | ||
| 2024-06-25 19:48 |
Regulatory Filings
Changes in Sector Classification of Listed Companies as of Sunday, June 30, 2024
|
Hebrew (modern) | 135.9 KB | ||
| 2024-03-21 18:45 |
Regulatory Filings
Will trade on Monday March 25 2024, with unlimited price fluctuation at the ope…
|
Hebrew (modern) | 137.2 KB | ||
| 2023-07-13 20:43 |
Regulatory Filings
Transfer to the Maintenance List on July 17, 2023
|
Hebrew (modern) | 149.7 KB | ||
| 2023-07-03 19:48 |
Regulatory Filings
Companies that do not comply with the Maintenance Rules and are candidates to b…
|
Hebrew (modern) | 116.3 KB | ||
| 2023-01-15 17:37 |
Regulatory Filings
Non-Compliance with the Maintenance Rules Based on Data as of December 31, 2022…
|
Hebrew (modern) | 132.9 KB | ||
| 2021-01-07 15:45 |
Regulatory Filings
On Sunday, 10 January 2021, trading will commence in the following Security: CA…
|
Hebrew (modern) | 186.1 KB |
Automate Your Workflow. Get a real-time feed of all Y.B Urban Renewal - Residential Development LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Y.B Urban Renewal - Residential Development LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Y.B Urban Renewal - Residential Development LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
Sweden
ACTI
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
United States of America
ACTU
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Sweden
ACUC
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
United States of America
ACXP
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
United States of America
ADAG
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
United States of America
ADAP
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
South Korea
179530
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
United States of America
ADCT
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
United States of America
ADIL
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
United States of America
ACET